Passage Bio Inc (NAS:PASG)
$ 0.7925 -0.0075 (-0.94%) Market Cap: 49.41 Mil Enterprise Value: -11.14 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Passage Bio Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 03:40PM GMT
Release Date Price: $1.99 (-6.13%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Thank you everyone for joining us today at the Goldman Sachs Global Healthcare Conference. Really thrilled to be joined by Simona King from Passage Bio to give us some update -- obviously the company's kind of in a point of transition so it's good to have someone join us and give us some update on where things are.

Simona King
Passage Bio, Inc. - CFO & Corporate Secretary

Excellent. Great to be here and thanks for having me.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Great. And I'll start at a very high level because I feel like with all these new biotechnology companies, it's good to have a high level view of the company. Walk us through Passage's approach to central nervous system AAV gene therapy and we could start I guess focus both on the technologies you are using but also some of the delivery methods that are kind of differentiating for Passage as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot